Real-world cost-effectiveness analysis of thymoglobulin versus no induction therapy in kidney transplant recipients at low risk of graft loss
The single 3 mg/kg dose of r-ATG is cost-effective in preventing acute rejection episodes and dominant in the long term of transplantation, conferring survival gain.
Authors
- Adrieli Bessa (ORCID: https://orcid.org/0000-0001-6987-2016)
- Renato Demarchi Foresto (ORCID: https://orcid.org/0000-0001-9370-0265)
- Hélio Tedesco‐Silva (ORCID: https://orcid.org/0000-0002-9896-323X)
- Marina Pontello Cristelli (ORCID: https://orcid.org/0000-0002-2813-0400)
- Cláudia Rosso Felipe (ORCID: https://orcid.org/0000-0002-8597-4466)
- Jose Osmar Medina-Pestana (ORCID: https://orcid.org/0000-0002-0750-7360)
- Marcelo Cunio Machado Fonseca (ORCID: https://orcid.org/0000-0003-0803-3715)
Institutions
- Universidade Federal de São Paulo (BR)
Publication Details
- Journal
- Brazilian Journal of Nephrology
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1590/2175-8239-jbn-2024-0060en
- Citations
- 5
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.54